VIRTUAL MEDZONE Your Resource for Hepatitis Related Innovative Medical Communication.

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.

Advertisements

Edited by Morris Sherman MD BCh PhD FRCP(C) Associate Professor of Medicine University of Toronto Protease Inhibitors in Chronic Hepatitis C: An Update.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Duration and Dose Finding Peginterferon alfa-2a + Ribavirin Phase 3 Treatment Naïve, Chronic HCV Randomized study.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIAID SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin for 12 or 24 Weeks in GT 2,3 Phase 3 Treatment Naïve, Chronic HCV Mangia A, et.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation Phase 2 Charlton M, et al. Gastroenterology.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:

ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:

Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

LDV/SOF 90/400 mg qd Non-randomised Open-label N = 21 W12 SVR 12 NIAID SYNERGY GT4 Kohli A. Lancet Infect Dis 2015; Juky 15, ePub ahead of print ≥ 18 years.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

ELECTRON  Design SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ELECTRON Study: SOF-based therapy for genotypes 1, 2 and 3 W8W4W12 ≥ 19 years Chronic.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study Phase 3 Treatment-Naïve and Treatment-Experienced Nelson DR,

How to manage G1 relapsers and non-responders George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal.

CASE 3 48 yo man HIV positive/HEP C positive 12 yrs ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs CD4 310/40% HIV Viral Load

FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =

ADAP and Hepatitis B Coverage  In June 2012, 29 ADAPs covered at least one of the medications for HBV on their formularies.  ADAPs filled 325 hepatitis.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

ARV-trial.com C-SWIFT Study: grazoprevir/elbasvir + SOF in genotypes 1 or 3, with or without cirrhosis Randomisation 1 : 1 Open-label Design W4 W6 W8.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Genotype 1 NIAID/NIH Trial Phase 2, Treatment Naïve Treatment Naïve (unfavorable.

CASE 3 62 yo man Genotype 1b chronic hepatitis C Cirrhosis No previous ascites/encephalopathy OGD revealed a few very small esophageal varices.

Hepatitis C Nonresponders

Hepatitis web study Hepatitis web study Sofosbuvir + RBV in Treatment-Naïve Genotypes 2,3 FISSION Trial* Phase 3 *Note: Published in NEJM in tandem with.

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2 Phase 2 Treatment Experienced Lawitz E, et.

Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir in GT1 with Cirrhosis OPTIMIST-2 Trial Phase 3 Treatment Naïve and Treatment Experienced.

LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.

CASE 3 48 yo man HIV positive/HEP C positive 12 yrs. ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs. CD4 310/40% HIV Viral Load

Placebo + PR W24 DCV + PR Placebo + PR Yes Dore GJ. Gastroenterology 2015;148: COMMAND GT2/3 COMMAND GT2/3 Study: daclatasvir + PEG-IFN + RBV for.

LDV/SOF Open-label Chronic HCV infection Genotype 1 Failure to achieve SVR 12 on a short-course of 1 st line LDV/SOF-containing regimen No cirrhosis N.

SOF/VEL 400/100 mg qd N = 106 W12 > 18 years Chronic HCV infection Genotype 1-6 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis allowed*

Hepatitis web study Hepatitis web study Elbasvir + Grazoprevir in GT 1 and Chronic Renal Disease C-SURFER Phase 3 Treatment Naïve and Treatment Experienced.

SOF + RBV GT2 Japanese SOF + RBV Open-label Japanese SOF + RBV Study: SOF + RBV in genotype 2  Design W12 Japanese patients ≥ 20 years Chronic HCV infection.

Phase 3 Treatment Experienced

Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Naïve GT 1-6 POLARIS-2

Where Are We on the Path to Elimination of Chronic Hepatitis C?

EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.

No HBV or HIV co-infection

Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study

PHOTON-2 Study: SOF + RBV in HCV-HIV co-infection

Phase 3b Treatment-Naive

Phase 2b Treatment-Naïve

SOF/VEL + GS-9857 in genotypes 1-6 Phase II

Phase 2 Treatment Naïve Injection Drug Use

HCV Care in Unique Patient Populations

History 56 y/o male from Cuba newly diagnosed with hepatitis C genotype 2b in Jan 2008 No symptoms of decompensation.

Phase 3 Treatment Naïve HIV Coinfection

(Treatment Failure Trial)

Phase 2 Treatment Naïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE Brown A, et al. EASL 2015; Abstract P0771.

Treatment with the second-generation HCV protease inhibitor BI results in high and consistent SVR rates: Results from SILEN-C1 in HCV genotype-1.

HCV Protease Inhibitors in Clinical Practice

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

ASPIRE Study: SMV + PEG-IFN + RBV for genotype 1 experienced patients

HCV Protease Inhibitors in Clinical Practice

Phase 2 Treatment Naïve Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve HCV Genotype 1 or 3 C-SWIFT Poordad F, et al. EASL 2015; Abstract O006.

Switch to LPV/r monotherapy

What Does the Future Hold and What Will It Mean for Patients?

Volume 140, Issue 7, Pages (June 2011)

Phase 2 Treatment Experienced (with Sofosbuvir and Ribavirin)

Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 3 Treatment-Naïve and Treatment-Experienced

Pei-Yuan Su，Yu-Chun Hsu，Shun-Sheng Wu，Wei-Wen Su，Maw-Soan Soon

Presentation transcript:

VIRTUAL MEDZONE Your Resource for Hepatitis Related Innovative Medical Communication

Hepatitis Case Presentations John Farley MD FRCPC Mike Silverman MD FRCPC David Fletcher MD FRCPC

CASE 1 47 yr-old man Genotype 1a chronic hepatitis C Compensated cirrhosis Baseline HCV RNA 3.65x10 7

CASE Treatment with PEGINF/RBV WEEKHCV RNA 03.65x x x10 7

CASE Neutropenia noted as of week 6 and GCSF 300mcg TIW administered Despite the above, admitted to hospital at week 12 with febrile neutropenia for 10 days – therapy discontinued

CASE Patient wants a trial of triple therapy Would you retreat? If so, with what and why?